What is HC Wainwright's Estimate for AXSM Q4 Earnings?

Key Points

• HC Wainwright lowered its Q4 2027 EPS estimate for Axsome Therapeutics to $2.53 from $2.81, while maintaining a “Buy” rating. The broader full-year consensus estimate is a loss of $2.78 per share.
• Analyst sentiment remains favorable, with Axsome holding a “Moderate Buy” consensus rating and an average price target of $267.60; recent targets range as high as $310.
• Axsome’s shares opened at $205.40, below their 50-day moving average of $231.17. In its latest quarter, the company reported a $0.99 per-share loss and $218.38 million in revenue, missing analyst estimates on both measures.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at HC Wainwright reduced their Q4 2027 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $2.53 per share for the quarter, down from their previous forecast of $2.81. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.78) per share.

Several other analysts have also recently issued reports on the stock. Morgan Stanley upped their price target on shares of Axsome Therapeutics from $242.00 to $251.00 and gave the company an "equal weight" rating in a report on Tuesday, August 11th. Wells Fargo & Company raised their price objective on shares of Axsome Therapeutics from $255.00 to $256.00 and gave the stock an "overweight" rating in a report on Tuesday, August 11th. TD Cowen boosted their target price on shares of Axsome Therapeutics from $275.00 to $300.00 and gave the stock a "buy" rating in a research report on Wednesday, June 17th. Royal Bank Of Canada cut their target price on shares of Axsome Therapeutics from $304.00 to $297.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 11th. Finally, BMO Capital Markets initiated coverage on Axsome Therapeutics in a research note on Monday, July 20th. They issued an "outperform" rating and a $310.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $267.60.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $205.40 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.34 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $10.76 billion, a price-to-earnings ratio of -54.77 and a beta of 0.65. The firm's fifty day simple moving average is $231.17 and its 200 day simple moving average is $206.29. Axsome Therapeutics has a twelve month low of $112.90 and a twelve month high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The firm had revenue of $218.38 million during the quarter, compared to analyst estimates of $221.11 million.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently made changes to their positions in AXSM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Axsome Therapeutics by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company's stock worth $2,557,000 after buying an additional 1,002 shares in the last quarter. Jones Financial Companies Lllp boosted its position in Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company's stock worth $889,000 after acquiring an additional 7,320 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company's stock worth $35,189,000 after purchasing an additional 84,151 shares in the last quarter. Caxton Associates LLP bought a new position in shares of Axsome Therapeutics in the first quarter worth $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Axsome Therapeutics by 29.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company's stock valued at $8,735,000 after purchasing an additional 17,250 shares during the period. Institutional investors and hedge funds own 81.49% of the company's stock.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 33,000 shares of Axsome Therapeutics stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total value of $7,922,970.00. Following the sale, the chief financial officer directly owned 42,867 shares in the company, valued at $10,291,938.03. This trade represents a 43.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roger Jeffs sold 286 shares of the business's stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total transaction of $70,407.48. Following the transaction, the director directly owned 58,653 shares of the company's stock, valued at $14,439,195.54. The trade was a 0.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 200,766 shares of company stock valued at $46,685,646 in the last three months. 20.60% of the stock is owned by corporate insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source